Print Page | Sign In | Join Today
News & Press: Company News

SBIR Grant Awarded to CEL-SCI for Potential RA Indication

Friday, July 18, 2014  
Share |
CEL-SCI Corporation (NYSE MKT: CVM) has been awarded a Phase I Small Business Innovation Research (SBIR) grant in the amount of $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases (NIAMS), of the National Institutes of Health (NIH). The grant will fund the further development of CEL-SCI’s LEAPS technology as a potential treatment for rheumatoid arthritis (RA), an autoimmune disease of the joints.

The NIH grant was awarded based on preliminary data by Tibor Glant, MD, Ph.D., and his team at Rush University Medical Center in Chicago, Illinois in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development and lessened the severity - including inflammation - of experimental RA when it was administered after the disease was induced in the animals.

The NIH grant will fund studies in a well-established mouse model for Th1 Proteoglycan induced arthritis (PGIA) as developed by Drs. Glant and Katalin Mikecz, MD, Ph.D. Professor of Orthopedic Surgery & Biochemistry. The studies were recently expanded to a Th17 PGIA by Drs. Glant and Allison Finnegan, Ph.D. Professor of Medicine. These two PGIA models are significant in that they more closely approximate human disease with the concurrent presence of rheumatoid factor and anti citrulline peptide antibodies and spondylitis that are not seen in most arthritis models.

Our Premium Partners

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected